Treatment of Malignant Phyllodes Tumour of Breast with Distant Metastasis

Malignant phyllodes tumour of the breast carries a meaningful risk of distant spread. When metastasis develops, the clinical picture shifts substantially and management priorities change — this page outlines the key considerations and the general therapeutic approach for this presentation.

Clinical scenario

Malignant phyllodes tumour of the breast with distant metastasis. Malignant phyllodes tumours carry a risk of distant metastasis of approximately 20%, most commonly to the lungs, typically occurring within two years of primary treatment. This presentation is managed in line with guidance for soft-tissue sarcoma (STS).

Treatment approach

For metastatic disease not amenable to local treatment, a palliative systemic chemotherapy approach is indicated. Full regimen details, sequencing, and agent selection are available in the complete protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/bjs/znaf152

Malignant PT also carry a risk of distant metastasis of approximately 20%, mostly to the lungs, which tends to occur within 2 years of primary treatment.

Metastatic malignant PT should be managed as per local guidelines for STS (evidence/grade V/A).

In the setting of metastatic disease not suitable for local treatment, chemotherapy (doxorubicin and/or ifosfamide) is often used with palliative intent.

View source ↗